Lazard Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-24,902
| Closed | -$1.19M | – | 2031 |
|
|
2025
Q3 | $1.19M | Sell |
24,902
-86,497
| -78% | -$3.48M | ﹤0.01% | 1083 |
|
|
2025
Q2 | $3.51M | Buy |
111,399
+88,881
| +395% | +$2.85M | ﹤0.01% | 837 |
|
|
2025
Q1 | $737K | Buy |
22,518
+19,631
| +680% | +$696K | ﹤0.01% | 1308 |
|
|
2024
Q4 | $104K | Sell |
2,887
-115
| -4% | -$4.05K | ﹤0.01% | 1791 |
|
|
2024
Q3 | $93K | Buy |
3,002
+797
| +36% | +$24.9K | ﹤0.01% | 1791 |
|
|
2024
Q2 | $58K | Sell |
2,205
-23
| -1% | -$667 | ﹤0.01% | 1903 |
|
|
2024
Q1 | $75K | Sell |
2,228
-9,753
| -81% | -$290K | ﹤0.01% | 1624 |
|
|
2023
Q4 | $346K | Buy |
11,981
+76
| +0.6% | +$2.02K | ﹤0.01% | 1214 |
|
|
2023
Q3 | $327K | Buy |
11,905
+7,508
| +171% | +$229K | ﹤0.01% | 1252 |
|
|
2023
Q2 | $132K | Buy |
+4,397
| New | +$154K | ﹤0.01% | 1475 |
|
|
2023
Q1 | – | Sell |
-1,748
| Closed | -$62K | – | 2540 |
|
|
2022
Q4 | $62K | Hold |
1,748
| – | – | ﹤0.01% | 1710 |
|
|
2022
Q3 | $59K | Sell |
1,748
-1,750
| -50% | -$56.9K | ﹤0.01% | 1729 |
|
|
2022
Q2 | $101K | Buy |
3,498
+1,460
| +72% | +$41.8K | ﹤0.01% | 1504 |
|
|
2022
Q1 | $65K | Buy |
2,038
+14
| +0.7% | +$429 | ﹤0.01% | 1615 |
|
|
2021
Q4 | $59K | Buy |
2,024
+274
| +16% | +$8.31K | ﹤0.01% | 1663 |
|
|
2021
Q3 | $46K | Sell |
1,750
-180
| -9% | -$4.83K | ﹤0.01% | 1719 |
|
|
2021
Q2 | $59K | Hold |
1,930
| – | – | ﹤0.01% | 1534 |
|
|
2021
Q1 | $50K | Buy |
+1,930
| New | +$54K | ﹤0.01% | 1436 |
|
|
2020
Q4 | – | Sell |
-2,461
| Closed | -$51K | – | 1979 |
|
|
2020
Q3 | $51K | Buy |
+2,461
| New | +$55.9K | ﹤0.01% | 1180 |
|
|
2020
Q1 | – | Sell |
-2,284
| Closed | -$54K | – | 1739 |
|
|
2019
Q4 | $54K | Buy |
2,284
+1,821
| +393% | +$44.2K | ﹤0.01% | 1038 |
|
|
2019
Q3 | $12K | Buy |
+463
| New | +$13.7K | ﹤0.01% | 1273 |
|
|
2018
Q3 | – | Sell |
-33,650
| Closed | -$2.01M | – | 1104 |
|
|
2018
Q2 | $2.01M | Hold |
33,650
| – | – | ﹤0.01% | 660 |
|
|
2018
Q1 | $1.54M | Sell |
33,650
-1,500
| -4% | -$62.6K | ﹤0.01% | 673 |
|
|
2017
Q4 | $1.4M | Sell |
35,150
-18,500
| -34% | -$731K | ﹤0.01% | 666 |
|
|
2017
Q3 | $2.15M | Sell |
53,650
-10,200
| -16% | -$441K | ﹤0.01% | 622 |
|
|
2017
Q2 | $2.75M | Sell |
63,850
-2,200
| -3% | -$78.3K | 0.01% | 594 |
|
|
2017
Q1 | $2.07M | Sell |
66,050
-77,250
| -54% | -$2.07M | ﹤0.01% | 652 |
|
|
2016
Q4 | $3.62M | Hold |
143,300
| – | – | 0.01% | 561 |
|
|
2016
Q3 | $3.54M | Hold |
143,300
| – | – | 0.01% | 564 |
|
|
2016
Q2 | $2.92M | Buy |
+143,300
| New | +$2.54M | 0.01% | 578 |
|
Other funds holding SUPN
AC
NAMI
Lazard Asset Management's SUPN Position: Q4 2025 in Review
Lazard Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 24,902 shares — an estimated $1.19M sold.
Lazard Asset Management first reported a position in SUPN in Q2 2016 and held it in 30 quarters. The position peaked at $3.62M in Q4 2016. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.
- Lazard Asset Management reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Lazard Asset Management sold 24,902 Supernus Pharmaceuticals shares in Q4 2025, an estimated $1.19M.
- Lazard Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2016 and held it in 30 quarters.
- Lazard Asset Management's Supernus Pharmaceuticals position peaked at $3.62M in Q4 2016.
- 333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.
Based on Lazard Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.